Immunome Inc. (IMNM) stock

IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30

$18.77+0.07 (+0.37%)

Close on Nov 13, 2026Market cap $2.13BP/E –Yield –

Immunome total assets

Total assets on the balance sheet at the end of each period.

Immunome's total assets was $505.53M at Sep 30, 2026. For fiscal 2025 it was $683.19M, up 184.4% from the year before. The highest annual figure on record is $683.19M in fiscal 2025.

Annual total assets

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$683.19M	+184.4%
FY2024	Dec 31, 2024	$240.24M	+61.7%
FY2023	Dec 31, 2023	$148.54M	+517.7%
FY2022	Dec 31, 2022	$24.05M	-58.5%
FY2021	Dec 31, 2021	$57.93M	+30.1%
FY2020	Dec 31, 2020	$44.53M	+779.9%
FY2019	Dec 31, 2019	$5.06M	–

Quarterly total assets

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$505.53M	+70.6%
Q1 FY2026	Mar 31, 2026	$619.79M	+80.9%
Q4 FY2025	Dec 31, 2025	$683.19M	+184.4%
Q3 FY2025	Sep 30, 2025	$299.38M	+16.5%
Q2 FY2025	Jun 30, 2025	$296.29M	+0.0%
Q1 FY2025	Mar 31, 2025	$342.69M	+7.2%
Q4 FY2024	Dec 31, 2024	$240.24M	+61.7%
Q3 FY2024	Sep 30, 2024	$256.90M	+175.8%
Q2 FY2024	Jun 30, 2024	$296.22M	+614.9%
Q1 FY2024	Mar 31, 2024	$319.75M	+564.6%
Q4 FY2023	Dec 31, 2023	$148.54M	+517.7%
Q3 FY2023	Sep 30, 2023	$93.16M	+205.0%
Q2 FY2023	Jun 30, 2023	$41.44M	+6.2%
Q1 FY2023	Mar 31, 2023	$48.11M	+0.8%
Q4 FY2022	Dec 31, 2022	$24.05M	-58.5%
Q3 FY2022	Sep 30, 2022	$30.55M	-51.2%
Q2 FY2022	Jun 30, 2022	$39.02M	-39.2%
Q1 FY2022	Mar 31, 2022	$47.73M	+12.1%
Q4 FY2021	Dec 31, 2021	$57.93M	+30.1%
Q3 FY2021	Sep 30, 2021	$62.56M	+422.1%
Q2 FY2021	Jun 30, 2021	$64.14M	+1167.6%
Q1 FY2021	Mar 31, 2021	$42.59M	–
Q4 FY2020	Dec 31, 2020	$44.53M	–
Q3 FY2020	Sep 30, 2020	$11.98M	–
Q4 FY2019	Dec 31, 2019	$5.06M	–